Lanum 667mg

Calcium acetate, a calcium salt, offers a range of benefits and features primarily in the management of hyperphosphatemia, a common complication of chronic kidney disease (CKD) and end-stage renal disease (ESRD). As a phosphate binder, Calcium acetate acts locally within the gastrointestinal tract to bind dietary phosphate, forming insoluble complexes that are excreted in the feces, thereby reducing serum phosphate levels. This mechanism helps prevent the systemic accumulation of phosphate, which can lead to mineral and bone disorders, cardiovascular complications, and other adverse outcomes associated with CKD and ESRD. By controlling hyperphosphatemia, Calcium acetate helps mitigate the risk of secondary hyperparathyroidism and renal osteodystrophy, promoting bone health and reducing the burden of cardiovascular morbidity and mortality in patients with advanced kidney disease.

Moreover, Calcium acetate’s efficacy as a phosphate binder is enhanced by its calcium content, which provides supplemental calcium to patients with CKD, who are often at risk of calcium deficiency due to impaired renal function and reduced intestinal absorption of calcium. This dual action of Calcium acetate in managing both hyperphosphatemia and calcium deficiency makes it a valuable therapeutic option in the comprehensive management of mineral and bone disorders associated with CKD and ESRD. Additionally, Calcium acetate’s favorable safety profile and minimal risk of systemic adverse effects make it a preferred choice for long-term phosphate control in these patient populations, offering renal healthcare providers a reliable and effective treatment option to optimize patient outcomes and improve quality of life.